Screener
Sutro Biopharma STRO Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -319.6%-123pp | -120%+257pp | -154.5%+230pp | -175.7%— | -196.3%— | |
| Net margin | -395.2%-195pp | -154.2%+215pp | -186.5%+180pp | -205.2%— | -199.8%— | |
| Efficiency | ||||||
| Asset turnover | 0.2×-0.1× | 0.4×+0.2× | 0.4×+0.2× | 0.3×0.0× | 0.3×-0.1× | |
| Liquidity | ||||||
| Current ratio | 3.3×+0.2× | 3.1×+1.0× | 2×-0.6× | 2.5×-0.6× | 3.1×-0.3× | |
| Per Share | ||||||
| Book value per share | -$6.23-65.3% | -$5.11-65.7% | -$15.59-370% | -$1.03-176% | -$3.77-301% | |
| Valuation | ||||||
| Market capitalization | $264.8M+246% | $412.69M+657% | $98.57M-35.0% | $73.62M-73.8% | $69.46M-70.8% | |
| Price / sales | 5.8×+5.1× | 4.1×+3.3× | 1×-1.5× | 0.7×-1.0× | 0.7×-0.7× |
FAQ
- Where do Sutro Biopharma's ratios come from?
- Every ratio is computed from Sutro Biopharma's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
